Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CVS Continues Preferred Status For Harvoni Over Viekira Pak

This article was originally published in The Pink Sheet Daily

Executive Summary

With the release of its formulary exclusions for 2016, CVS Health continues to prefer Gilead's HCV treatment over AbbVie's; just last week, Express Scripts continued with the opposite.

You may also be interested in...



Large Employer Drug Contracting Block Could Challenge Manufacturers, PBMs

Express Scripts has been talking to members of the Health Transformation Alliance about negotiating pricing on behalf of the group, which includes 20 large employers providing health benefits for four million individuals.

Large Employer Drug Contracting Block Could Challenge Manufacturers, PBMs

Express Scripts has been talking to members of the Health Transformation Alliance about negotiating pricing on behalf of the group, which includes 20 large employers providing health benefits for four million individuals.

Praluent Coverage: Being First May Not Matter As Payers Await Repatha

The pricing advantage that might have been available to Praluent as first-in-class is undercut by the fact that it only has about a month’s lead time over the competition.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS078874

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel